L & S Advisors’s Repare Therapeutics RPTX Stock Holding History

L & S Advisors’s Portfolio RPTX Stock Details RPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-7,500	Closed	-$257K	–	386
2020 Q4	$257K	Buy	+7,500	New	+$224K	0.03%	298

Other funds holding RPTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

L & S Advisors's RPTX Position: Q1 2021 in Review

L & S Advisors sold out of Repare Therapeutics (RPTX) in Q1 2021, closing a stake of 7,500 shares — an estimated $257K sold.

L & S Advisors first reported a position in RPTX in Q4 2020 and held it in 1 quarter. The position peaked at $257K in Q4 2020. 65 funds tracked by Wall St. Rank hold RPTX as of Q1 2021.

L & S Advisors reported no remaining Repare Therapeutics position as of Q1 2021 after selling out during the quarter.
L & S Advisors sold 7,500 Repare Therapeutics shares in Q1 2021, an estimated $257K.
L & S Advisors first reported a position in Repare Therapeutics in Q4 2020 and held it in 1 quarter.
L & S Advisors's Repare Therapeutics position peaked at $257K in Q4 2020.
65 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2021.

Based on L & S Advisors's 13F filing for Q1 2021, filed 10 May 2021.